Related Experiment Video
Updated: May 30, 2026
12:24
Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes
Published on: June 3, 2014
Stable expression of native Coagulation factor VIII using the 2A self-processing sequence and furin cleavage site
Bangshun He1, Yuqin Pan, Liping Chen
1The Central Laboratory of Nanjing First Hospital Affiliated to Nanjing Medical University, Nanjing, 210006, Jiangsu Province, China.
Thrombosis Research
|August 2, 2011
Summary
Bioengineered Factor VIII (FVIII) shows improved expression for hemophilia A treatment. Novel cleavage sites enhance FVIII heavy and light chain assembly, boosting therapeutic potential.
Area of Science:
- Biochemistry
- Molecular Biology
- Hematology
Background:
- Hemophilia A is a prevalent X-linked bleeding disorder.
- Current FVIII replacement therapy faces expression limitations.
- Bioengineered FVIII aims to enhance activity and stability.
Purpose of the Study:
- To engineer a more efficient FVIII expression system.
- To facilitate equimolar expression of FVIII chains.
- To improve FVIII molecule assembly and function.
Main Methods:
- Utilized a furin cleavage site (RKRR) and FMDV 2A peptide.
- Constructed a single open reading frame (ORF) for FVIII expression.
- Retained N-linked oligosaccharides in the B-domain spacer.
Main Results:
- Achieved efficient equimolar expression of FVIII heavy and light chains.
- Demonstrated self-assembly of functional FVIII molecules in vitro and in vivo.
- Observed enhanced FVIII expression in vitro and in a mouse model of hemophilia A.
Conclusions:
- Furin cleavage site and 2A peptide enable efficient FVIII expression.
- Optimized FVIII structure improves in vitro and in vivo performance.
- This strategy offers a promising approach for hemophilia A therapy.
Related Concept Videos
01:16Clot Retraction and Fibrinolysis
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
01:20Extrinsic and Intrinsic Pathways of Hemostasis
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...